Cost-Effectiveness of Introducing Nuvaxovid to COVID-19 Vaccination in the United Kingdom: A Dynamic Transmission Model

Cost-Effectiveness of Introducing Nuvaxovid to COVID-19 Vaccination in the United Kingdom: A Dynamic Transmission Model

<b>Background/Objectives:</b> Vaccination against SARS-CoV-2 remains a key measure to control COVID-19. Nuvaxovid, a recombinant Matrix-M–adjuvanted protein-based vaccine, showed similar efficacy to mRNA vaccines in clinical trials and real-world studies, with lower rates of reactogenici...

Full description

Saved in:
Bibliographic Details
Main Authors: Clive Pritchard, Lucie Kutikova, Richard Pitman, Kira Zhi Hua Lai, Hadi Beyhaghi, IIana Gibbons, Amanda Erbe, Marija Živković-Gojović, Catherine Cosgrove, Mark Sculpher, David Salisbury
Format: Article
Language:English
Published: MDPI AG 2025-02-01
Series:Vaccines
Subjects:
SARS-CoV-2
COVID-19 vaccines
dynamic transmission
cost-effectiveness
cost-utility
COVID-19
Online Access:https://www.mdpi.com/2076-393X/13/2/187
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2076-393X/13/2/187

Similar Items